FindMyKOL
Clinical trialNCT03858322Active, not recruitingPhase 1Interventional

'ADVANCE' (A Pilot Trial)

NCT03858322 is a phase 1 interventional trial sponsored by Dana-Farber Cancer Institute. As of 18 Nov 2026, it is active and no longer recruiting. It studies Carboplatin, Cyclophosphamide and Paclitaxel in Breast Cancer. The registry lists an enrollment of 41 participants at 5 sites in 1 country. The registry lists a start date of 21 Mar 2019 and a primary completion date of 10 Nov 2020.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03858322
FieldValue
Registry IDNCT03858322
StatusActive not recruiting
PhasePhase 1
Study typeInterventional trial
Lead sponsorDana-Farber Cancer Institute
Enrollment41
Registered sites5
Countries1
ConditionsBreast Cancer
DrugsCarboplatin, Cyclophosphamide and Paclitaxel
Start21 Mar 2019
Primary completion10 Nov 2020
Study completion30 Dec 2026
Last update posted13 Aug 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is being conducted to carefully study how chemotherapy is tolerated in group of patients age 70.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

California, United States1 site
  • City of Hope National Medical Center

    Duarte

Massachusetts, United States3 sites
  • Dana Farber Cancer Institute

    Boston

  • Dana-Farber/brigham and Women's Cancer Center (df/bwcc) at Milford Regional Medical Center

    Milford

  • Dana-Farber/brigham and Women's Cancer Center (df/bwcc) in Clinical Affiliation With South Shore Hospital

    South Weymouth

North Carolina, United States1 site
  • Novant Health Oncology Specialists

    Winston-Salem

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusetts: 3 sitesMA3Rhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCalifornia: 1 siteCA1NevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth Carolina: 1 siteNC1South CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03858322

Each answer restates registry values shown on this page.

What is NCT03858322?

NCT03858322 is a phase 1 interventional trial sponsored by Dana-Farber Cancer Institute. It studies Carboplatin, Cyclophosphamide and Paclitaxel in Breast Cancer.

Is NCT03858322 recruiting?

As of 18 Nov 2026, it is active and no longer recruiting.

Who leads NCT03858322?

The registry names Rachel Freedman, MD, MPH (principal investigator, Dana-Farber Cancer Institute) as the overall official.

Where does NCT03858322 run?

The registry lists 5 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT03858322 study?

The registered drug and biological interventions are Carboplatin, Cyclophosphamide and Paclitaxel.

When is NCT03858322 expected to complete?

The registry lists a primary completion date of 10 Nov 2020 and a study completion date of 30 Dec 2026. The sponsor last updated the record on 13 Aug 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.